Credit for Continuing Medical Education
The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.
Credit Designation Statement
AACR has designated this live activity for a maximum of 15 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.
Claiming (CME) Credit
Physicians and other health care professionals seeking AMA PRA Category 1 Credits™ for this continuing medical education activity must complete the online CME Request for Credit Survey by , June 21, 2019.
Certificates will only be issued to those who complete the survey. A link to the request-for-credit survey is available at the link below and via email.
Your CME certificate will be sent to you via email after the completion of the activity.
Statement of Educational Need, Target Audience and Learning Objectives: This course provides a comprehensive review of agent (including drugs and biological) development including pre-clinical and clinical evaluation, and regulatory procedures and endpoints required to bring discovery into clinical use that provides benefit to patients. Few individual investigators have the entire scope of this knowledge, and this workshop integrates this knowledge with real-life examples and specifically illustrates the role that the community, including the investigator, plays in the process from discovery to approvals and beyond. Only one agent is successfully produced for every 20 that enter into clinical evaluation. The workshop will impart the knowledge necessary to enable successful clinical researchers to develop the expertise in the entire spectrum of drug development by honing strategic planning skills with a focus on target validation and pathway identification that will lead to advances in the entire field of cancer research. This workshop:
- Seeks to improve the efficiency of testing and increase the success rate of development plans for agents that provide benefit to patients.
- Provides an opportunity for open dialogue between regulatory agencies and the oncology community including physician-scientists.
- Encourages creative thinking in addressing current challenges and developing useful and informative oncology clinical trials.
Following this learning activity, participants should be able to:
- Assess the key decision points in determining if an anticancer agent or combination has clinical benefit.
- Analyze and more effectively follow FDA safety and efficacy guidelines during the development and clinical testing of anticancer and cancer prevention drugs, and in the long-term safety evaluation of these.
- Design and participate in oncology clinical trials with meaningful endpoints and accrual goals.
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this workshop.
Questions about CME?
Please contact the AACR Office of CME at (215) 440-9300 or email@example.com.